# Apremilast and Adalimumab in Psoriatic Arthritis Patients

> **NCT07398651** · NA · NOT_YET_RECRUITING · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Psoriatic Arthritis
- Ultrasound Assessment
- TNF

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT07398651
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07398651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07398651, "Apremilast and Adalimumab in Psoriatic Arthritis Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07398651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*